WikiSWOT.com :: Free Genzyme SWOT Analysis

User Generated >> Genzyme SWOT Analysis:

Strengths Passionate, visionary, long term (~25 years) CEO High R&D Innovation Loyal customers Market share leadership Strong brand equity Strong financial position Pricing Unique products Market leader in the treatment of rarely inherited genetic diseases Robust clinical data to support product efficacy Very few players in the category so less competition	Weaknesses Diseconomies to scale Weak, damaged brand Small patient base (Rarely inherited diseases) High dependence on very few products (Cerezyme & Fabrazyme) Prohibitive costs of therapy per patient ($200,000/year) Manufacturing issues Growth by acquisitions hence lacks integration of different parts of organization
Opportunities Acquisitions Financial markets (raise money through debt, etc) Emerging markets and expansion abroad Innovation New Therapeutic Indications Increasing focus on core business New product approvals by FDA Reimburt opportunities	Threats Competition External changes (government, politics, taxes, etc) Emerging small molecule products Product inventory concerns Long product development cycle Increasingly tighter controls on life sciences industry High R&D costs Increasing regulatory pressures

History: Version 4 (Newest), Version 3, Version 2, Version 1 (Oldest)

Go back to the SWOT analysis index, or start a discussion about Genzyme SWOT analysis by adding a comment below WikiSWOT Comments

Name
Email (not shared)
Website

Add comment